New Delhi: India is once again seeing a rise in covid. The Drugs Controller General of India granted restricted emergency use authorization to Bharat Biotech’s Covaxin for children aged 6 to 12 years. In December 2021, the panel approved Covaxin for emergency use in children above 12 years.
For vaccination, the Company has been asked to submit safety data. The company has been requested to report adverse event data, every 15 days for the first two months and then monthly for the next five months.
On April 21, Bharat Biotech was asked to submit additional data on the administration of Covaxin for kids in the 2-12 years age group. This appeal was made by the Subject Expert Committee (SEC) of DCGI.
At that time only emergency use of Corbevax for children in the five to 12 years age group, was approved by the panel. Meanwhile, Zydus Cadila’s ZyCoV-D vaccine has also been granted restricted emergency use authorization for children above the age of 12 years.
Union health minister Mansukh Mandaviya, taking to Twitter wrote, “India’s fight against Covid is now stronger. Central Drugs Standard Control Organisation has granted restricted emergency use authorization to Covaxin for 6-12 years age group, Corbevax for 5-12 years age group, and ZyCoV-D for those above 12.”
With 2,483 new coronavirus infections being reported in a day, India’s total tally of COVID-19 cases rose to 4,30,62,569, while the active cases dipped to 15,636, according to the Union Health Ministry data updated today.
The number of deaths climbed to 5,23,622 with 1,399 new fatalities as Assam reconciled 1,347 deaths and Kerala 47 due to the infection, the data updated at 8 am stated.
“The total cases, discharge, and deaths provided by Assam in its media bulletin have been considered along with the number of Covid positive patients died due to other reasons to reflect the current figures. The state has reported zero deaths in the last 24 hours,” the Union Health Ministry said.
As an independent media platform, we do not take advertisements from governments and corporate houses. It is you, our readers, who have supported us on our journey to do honest and unbiased journalism. Please contribute, so that we can continue to do the same in future.
